Niagen Bioscience, Inc. · NASDAQ:NAGE
Niagen Bioscience — ChromaDex — Investor Presentation (March 2018)
30 slides from Niagen Bioscience's investor presentation, Mar 12, 2018
Slide 1: Investor Presentation
st Investor Presentation Nasdaq: CDXC | March 2018
Slide 2: Disclaimers
Disclaimers This presentation and other written or oral statements made from time to time by representatives of ChromaDex contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. Forward-
Slide 3: Slide 3
Slide 4: The Science of Youth
The Science of Youth * Pioneering technologies that improve the way we age. * Focused on NAD and its central role in the maintenance of human health. * NIAGEN® is our propriety compound that is clinically shown to be a highly efficient way to safely elevate levels of NAD. * Scientific Advisory Board
Slide 5: The Critical Role of NAD
S crromadex The Critical Role of NAD * Nicotinamide adenine dinucleotide (NAD) is a coenzyme found in every living cell. * NAD is mission-critical for cellular health. * NAD declines as we age. * When NAD levels are low, cells don’t function optimally. * Scientists now understand that low NAD or rel
Slide 6: NAD Levels Respond to Stress
NAD Levels Respond to Stress Scientists attribute declines NAD levels rise cS in NAD to age-associated * Calorie restriction/fasting 38 pathologies. * Glucose deprivation = 19 + Exercise Sel £5 Big NAD levels decline a 7" * Aging = ps Obesity/overnutrition * Noise injury Alcohol al a Mitochondrial d
Slide 7: Declines in NAD are Documented in a Wide Range of Conditions
Declines in NAD are Documented AGING Brain ~63-90% Cerebral spinal fluid ~91% Heart ~30-40% Liver ~40-90% Pancreas ~80-85% DUCHENNE MUSCULAR DYSTROPHY MODEL Muscle ~45-75% e + Spl 35-40% in a Wide ney 15.208 — HEART FAILURE Range of ee Conditions OBESITY Liver unchanged ~85% ‘Muscle unchanged ~85% N
Slide 8: Our Solution
Our Solution : Safe NIAGEN is the only proprietary nicotinamide riboside approved as a New Dietary Ingredient and that has achieved GRAS status Effective NIAGEN increases NAD Patented 14 licensed global patents or patents pending
Slide 9: NIAGEN Raises NAD Levels in Humans
NIAGEN Raises NAD Levels in Humans Human Clinical Conclusions * NIAGEN raised levels of NAD in a dose response fashion * Levels remained elevated over duration of the study * Confirmed safe for daily use NAD CONCENTRATION (MG/ML) 55 50 1000 mg 4s 40 = 300 mg 30 25 100mg 20 Placebo Baseline Week 1 We
Slide 10: Areas of Study and Research Progress on NR
+ Alzheimer’s Disease * Diabetes + Melanoma + Heart Failure + Diabetic Neuropathy * Steatosis Areas of = Weight Loss * Parkinson's Disease + Immune Response Study + Breast Cancer + Traumatic Brain Injury + Muscle Physiology + Chemotherapy Induced + Mitochondrial Myopathy + Browning of Adipocytes Neu
Slide 11: Pre-clinical and Clinical Research
Pre-clinical Research N>>100 More than 100 publications contain ‘nicotinamide riboside’ in the title or abstract listed on Pub Med. Investigations Sixteen trials are registered on clinicaltrials.gov At least 7 more are in planning and not yet registered NIAGEN® has Reached the Significant Milestone
Slide 12: Most Prominent Human Clinical Research Areas for NIAGEN
Brain, Cardiovascular Health, and Obesity are the Most Prominent Human Clinical Research Areas for NIAGEN® NEUROLOGICAL CARDIOVASCULAR OBESITY # of Human Studies N=7 Nea N=2 Mild cognitive impairment (Alzheimer’s disease) Hypertension Insulin sensitivity Conditions Studied Newrofetiy Pals Arterial s
Slide 13: Our Scientific Advisory Board
Our Scientific Advisory Board Charles Brenner, Ph.D. Head of Biochemistry University of lowa World's Foremost ‘Authority on NAD Metabolism, Dr. Bruce German Chairman of Food, ‘Nutrition, & Health Leader in Food, Nutrition, & Wellness Innovation Roger Kornberg, Ph.D. Professor of Structural Biology S
Slide 14: Strong Patent Protection
Strong Patent Protection * 14 licensed global patents or patents pending, including: * Synthetic manufacture of NR Manufacture of NR via recombinant microorganisms NR for increasing NAD+ biosynthesis Compositions comprising NR NR for treatment diseased and/or injured neurons * Continue to invest in
Slide 15: The Business of Youth
The Business of Youth * Billions spent worldwide on Looking, Acting and Feeling Younger * Anti-Aging Market was $250 billion worldwide in 2016! * Skin care, cosmetic surgery, hair restoration, fitness, vitamins & supplements, etc. * Gym memberships - $28 billion US?, $84 billion global? * Cosmetic s
Slide 16: TRU NIAGEN Brand
TN TRU NIAGEN Brand SCIENTIFIC + Breakthrough Science + Leading Scientists + Thought Leaders TRUSTWORTHY + TRU NIAGEN is safe + TRU NIAGEN works. + Transparent
Slide 17: Growth Drivers
y Growth Drivers Higher Consumer Growing Body Expanding Expanding Enter New of Human Awareness of Distribution Clinical ACESS TRU NIAGEN® with Strategic HOPES) Brand Partners in NIAGEN New Global & Markets TRU NIAGE Categories : Medical Food, Fortified Food & Beverages, Pet Food, Measuring Devices,
Slide 18: Our Target Consumer
JOAN AGE 55+, HEALTHY Desires — Easing concerns about the long term effects of aging and staying well. Our Target Consumer SARAH AGE 40-50 Desires — Maintaining youthful appearance and staying physically active. CHARLIE AGE 40-55 Desires - Optimizing health to perform at mentally and physically peak
Slide 19: e-Commerce and Marketing
U.S. e-Commerce Marketing truniagen. com Amazon.com + Online Shopping CONSUMER Sponsored Content Paid Search Influencers + + Display Key Opinion Advertising Leaders
Slide 20: Building a Global Brand
buitcine a Global Brand = i HERRERA operatic we ci tee ee, } itt ite HONG KONG =) _ Watsons. ete ees, an 4 “ SINGAPORE Yii:. .:. ett Watsons Je PARTNE! Bete HE at . tities i i : Ce HERE & fests = be: og ia i NASDAQ: CDXC 20
Slide 21: Management
Management Frank Jaksch Team Chief Executive Officer Rob Fried President, Chief Operating Heide Kevin Farr Chief Financial Officer Mark Friedman General Counsel, Corporate Secretary Amy Boileau, Troy Rhonemus Executive Vice PhD., RD President Vice President, Research & Development
Slide 22: NASDAQ: CDXC 22
NASDAQ: CDXC 22
Slide 23: Recent Results: 2017 vs. 2016
Recent Results: 2017 vs. 2016 Net Revenues ($M) % of Revenue Zs 5 | a4 Q4 2016 Results i Q42016 Q4 2017 2% Full Year Results Net Revenues ($M) % of Revenue o' $21.7 ——> $212 NASDAQ: CDXC 23
Slide 24: Recent Results: 2017 vs. 2016 cont'd
Recent Results: 2017 vs. 2016 cont’d Q4 Operating Performance > We continue to invest ahead of growth in R+D, marketing and G+A Gross Margin ‘Total Operating. ‘Operating Loss ($M) (1) 4D (SM) pepe (sm) Marketing ($M) G+A(SM) ey menses) a six 3 ; - (2) $12.6 Q42016 ©. Q42017 45% i ss ra Z = 4 $3.3 $4
Slide 25: Comparable Products
COMPARABLE PRODUCTS In our target markets: $49.1 B in dietary supplements $8.3 B in “tonics” $3.1 B in Vitamin B $1.3 B in Vitamin D $3.0 B in Fish Oil 1.6% of total = $1.04 billion in annual TRU NIAGEN® sales THE BUSINESS OF YOUTH Globally Anti-aging spending is $250 billion per year (skin care, co
Slide 26: 2018 Outlook
2018 Outlook * Started 2018 with $45 million in cash * Significant growth, skewed to back-half of year. * Gross profit % of net sales expanding * Investment spending ahead of revenue growth * Marketing * Global infrastructure * Capabilities * R&D * Protecting/managing patent portfolio and trademarks
Slide 27: Case Study: Martek and Omega
Case Study: Martek and Omega 3 Demand for fish oil rising ($ Millions) Martek Sales From 2002 to 2006 ‘Annual sales of fish oil and $300 ‘omega fatty acid supplements, inbillions of dollars CAGR 54% aid 4 $250 10 $204 $200 gi7a $150 Os: $112 $100 013 ° EE a a 200 zou | Source: Euromonitor THE WASHNG
Slide 28: Key Statistics
Key Statistics Trading Data (@ mars, 2018) Stock Price $5.16 52 Week High/Low $7.24/$2.26 Avg. Daily Vol. (3 mo.) 466,635 Shares Outstanding 53.8M Public Float (excl. >5% owners) 63% Insider Holdings 37% Market Cap $277.6M Enterprise Value* $232.2M EV/Revenue (iT) 11.0X EV/Adj. EBITDA (ut) N/M P/E (
Slide 29: Contact Info
Contact Info Andrew Johnson Director of Investor Relations T: +1.310.388.6706 Ext. 661 AndrewJ@chromadex.com www.chromadex.com
Slide 30: Slide 30